Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The investigators intend to conduct a randomized controlled study to find if combining HIPEC
(hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy D2
resection could improve survival for patients with advanced gastric cancer, while comparing
with the traditional approach of D2 resection after neoadjuvant chemotherapy.